Armed with some of the world’s most advanced instrumentation, researchers at PNNL are working to analyze huge amounts of data and uncover hidden biological connections.

PNNL biodefense experts seek to identify, understand and mitigate the risks of biological pathogens—whether naturally occurring or intentionally created—so steps can be taken to prepare and respond.

Research at PNNL and the University of Texas at El Paso are addressing computational challenges of thinking beyond the list and developing bioagent-agnostic signatures to assess threats.

Scientists have learned more about how drug resistance develops in patients with acute myeloid leukemia and how the process might be slowed.

At the Nonproliferation, Counterproliferation, and Disarmament Science Gordon Research Conference, researchers from PNNL shared research and scientific approaches for countering diverse threats.

A detailed snapshot of proteins by PNNL scientists marks a big step toward a diagnostic blood test for a deadly form of liver disease.

PNNL Biomedical Scientist Geremy Clair has taken on new roles as an editor for two journals; Frontiers In Cellular And Infection Microbiology and Frontiers In Molecular Biosciences.

Governor Inslee announced the appointment of Karin Rodland to the Board of Directors of the Andy Hill Cancer Research Endowment Fund.

One year ago, Verizon announced a partnership that made PNNL the U.S. Department of Energy’s first national laboratory with Verizon 5G ultra-wideband wireless technology.